Summary
Axon Enterprise, Inc. (formerly TASER International, Inc.) reported a net sales increase of 24.1% to $55.5 million for the first quarter of 2016 compared to the prior year, driven by strong performance in both its TASER Weapons segment (up 19.5%) and its Axon segment (up 51.0%). The Axon segment's growth was particularly notable, fueled by a significant increase in Evidence.com recurring revenues and strong bookings for new products, despite a temporary dip in recognized camera revenue due to the introduction of the Axon Body 2. While gross margins remained stable year-over-year at 66.5%, operating expenses saw a substantial increase, primarily in Sales, General & Administrative (SG&A) and Research & Development (R&D) expenses. This increase is attributed to investments in expanding sales teams, product development for the growing Axon segment, and increased marketing efforts. Consequently, net income decreased to $3.5 million ($0.06 per diluted share) from $7.2 million ($0.13 per diluted share) in the prior year's quarter, reflecting the higher operating expenses. The company also repurchased approximately $9.0 million of its common stock under a new $50 million repurchase program. Financially, the company maintained a healthy liquidity position with $114.1 million in cash, cash equivalents, and investments at quarter-end, and no outstanding borrowings on its $10 million credit line. Despite the decrease in net income, the growth in net sales and bookings, particularly in the burgeoning Axon segment, indicates positive momentum for the company's strategic expansion into digital evidence management solutions.
Financial Highlights
48 data points| Revenue | $55.53M |
| Cost of Revenue | $18.63M |
| Gross Profit | $36.90M |
| R&D Expenses | $6.93M |
| SG&A Expenses | $24.83M |
| Operating Expenses | $31.76M |
| Operating Income | $5.14M |
| Net Income | $3.46M |
| EPS (Basic) | $0.06 |
| EPS (Diluted) | $0.06 |
| Shares Outstanding (Basic) | 53.69M |
| Shares Outstanding (Diluted) | 54.79M |
Key Highlights
- 1Net sales increased by 24.1% to $55.5 million in Q1 2016 compared to Q1 2015, driven by growth in both TASER Weapons and Axon segments.
- 2The Axon segment showed robust growth, with net sales up 51.0% and Evidence.com recurring revenues increasing significantly.
- 3Gross margin remained stable at approximately 66.5% of net sales, indicating strong pricing power or cost management.
- 4Operating expenses, particularly SG&A and R&D, increased significantly (70.5% and 52.0% respectively), reflecting investments in sales expansion and product development.
- 5Net income decreased to $3.5 million ($0.06/share) from $7.2 million ($0.13/share) year-over-year due to higher operating expenses.
- 6The company launched a $50 million stock repurchase program and repurchased $9.0 million of common stock in Q1 2016.
- 7Strong bookings for Axon products and Evidence.com services ($52.1 million) indicate future revenue potential, a 126.9% increase from the prior year.